. In all but two of these studies, the treatment benefitted both groups (Logemann et al., 2010; Vollebregt et al., 2014) . A recent triple-blind registered randomized controlled trial (RCT) with 118 participants diagnosed with ADHD found large effect sizes for both true (d=1.0) and sham (d=1.5) neurofeedback groups (Schönenberg et al., 2017) . Until research demonstrates additional benefits from true neurofeedback that go above and beyond placebo effects, the science suggests that EEG-nf, at least in its current incarnation, relies exclusively on treatment mechanisms unrelated to watching one's own brain activity (Thibault & Raz, 2016) . EEG-nf, in other words, is neurosuggestion.
We already prescribe suggestion
Most clinicians have prescribed suggestion-but many don't know it. The benefits of SSRIs for depression, acupuncture for lower back pain, and knee surgery for osteoarthritis all stem largely from the suggestion that these treatments will improve your health (i.e., from placebo effects). In 2002, the psychologist Irving Kirsch obtained unpublished clinical trial data under the Freedom of Information Act, and found that SSRIs barely outperformed placebos in RCTs (Kirsch, Moore, Scoboria, & Nicholls, 2002) . In the case of lower back pain, two RCTs with a total of over 1,700 participants demonstrated comparable benefits between veridical acupuncture and sham acupuncture, yet both outperformed a standard-of-care treatment (Cherkin et al., 2009; Haake, Basler, & Endres, 2007; Harris, Lifshitz, & Raz, 2015) . Likewise, a highprofile RCT showed that, even at a two-year follow-up, sham knee surgery decreased pain and improved movement capacity on par with real surgery (Moseley et al., 2002 ). An expert panel now strongly recommends against knee surgery for osteoarthritis due to potential complications and the absence of benefits beyond placebo effects (Siemieniuk et al., 2017) . In these situation, clinicians often unknowingly prescribe placebos. Following the results from recent double-blind studies, we can now add EEG-nf for ADHD to this list of placebo therapies that masquerade under other biomedical labels.
The case for suggestion in ADHD
In contrast to the abovementioned placebo therapies, psychostimulants typically reduce ADHD symptoms more effectively than placebo, but come at a cost. Potential side-effects include crying, staring, anxiety, sadness, nail biting, euphoria, and shyness (Konrad-Bindl, Gresser, & Richartz, 2016) . Due to growing concerns about long-term adverse side-effects, the European Commission recently called for a two-year longitudinal study that is taking place at 27 sites (Inglis et al., 2016) . Given the potential for harm, it is advantageous to consider drug-free treatments with minimal side-effects to complement or replace psychostimulants. In this vein, a pair of studies found that when children with ADHD were prescribed an "open-label" placebo, they could cut their psychostimulant intake in half with negligible changes in behavior (Sandler & Bodfish, 2008; Sandler, Glesne, & Bodfish, 2010 (Sandler & Bodfish, 2008, p.106) Full disclosure made little impact on the effectiveness of the placebo condition-i.e., administering placebos openly hardly detracted from the clinical benefit (Sandler et al, 2008) .
Researchers have reproduced this finding in several conditions, including irritable bowel syndrome, chronic pain, and depression (Kaptchuk et al., 2010; Kelley, Kaptchuk, Cusin, Lipkin, & Fava, 2012; Schafer, Colloca, & Wager, 2015) .
Based on staunch faith in brain science, neurosuggestion may perhaps treat patients even better than placebo pills. In particular, with EEG-nf for ADHD, the suggestion that physical movement will contaminate the expensive brain recordings can lead participants to sit still and in turn, this procedure provides an ulterior form of behavioral therapy. The additional psychosocial cues surrounding EEG-nf, compared to those present when ingesting a pill, may help this technique compete with standard pharmacotherapy (e.g., Fuchs, Birbaumer, Lutzenberger, Gruzelier, & Kaiser, 2003) . To further support this point scientifically and to the level of clinical recommendation, more studies would need to directly compare EEG-nf with standard of care treatment.
Testing neurosuggestion in the clinic
In our previous work, we explored how strong this type of suggestion could be. We found that many participants believed that a crudely-built "brain scanner"-assembled from discarded hair drying and medical equipment and placed in a cognitive neuroscience laboratory-could read their minds (Ali, Lifshitz, & Raz, 2014) . In subsequent iterations of this paradigm, we found that a more realistic looking scanner could similarly alter people's sense of agency and moral attitudes (Olson, Landry, Appourchaux, & Raz, 2016; Olson, Strandberg, Hall, Johansson, & Raz, 2017) . In light of these findings, we decided to test the clinical applications of this technique we term neurosuggestion.
To pilot the idea, we used a real but decommissioned-in other words, sham-Magnetic Resonance Imaging (MRI) scanner at the Montreal Neurological Institute as part of an openlabel procedure to treat nine children diagnosed with ADHD (Figure 1 ; Veissière, Olson, & Raz, 2017) . We told the children that the "brain machine" was inactive, and that we would "use it as a suggestion" that would "help their brain heal itself". While in the defunct scanner, we gave the children positive verbal suggestions to promote relaxation, focus, and confidence. At one-three-, and six-week follow-ups, parents reported improvements in eight out of the nine participating children. In qualitative interviews, two families reported near complete remission of symptoms, and six reported improvements in areas such as confidence, self-control, and social skills. None reported any side effects. In essence, this study provided neurofeedback-like treatment, but instead of focusing on a specific physiological mechanism, we emphasized suggestion based healing. 
Should we prescribe EEG-nf for ADHD?
To answer this question, we need to consider a few issues. First, as a culture, we maintain deep-set beliefs that the origin of behavioral disorders resides in the brain (Moncrieff, 2016; Rose, 2003) . Relying on this assumption, children and their families often actively seek a diagnostic label, for example ADHD, in order to ascribe meaning to their behavior (Moncrieff, 2016; Moncrieff, Rapley, & Timimi, 2015) . Second, even in our open-label neurosuggestion experiment , parents continued to ask what was "wrong" with their child's brain, despite having been extensively briefed regarding the inert nature of the MRI scanner. And yet, this very belief system-that a brain disorder is the core reason for the symptoms-may unintentionally act as a suggestion to further obfuscate the situation and exacerbate symptoms through nocebo effects (Loftus & Fries, 1979) . This type of thinking has been described as a "looping effect", where our beliefs and social norms affect the framing, course, and outcomes of a disorder (Hacking, 1995) . In other words, context and culture strongly modulate how patients attend to and construe their behavior, which in turn, alters their symptoms (Kirmayer, GomezCarrillo, & Veissière, 2017; Seth & Friston, 2016) . Third, our experiments show that brain-based folk explanations can lead to both nocebo and placebo effects. It seems that neurofeedback likely summons its strength from this belief system, which offers a promising means to regulate "faulty" brain patterns (Thibault & Raz, 2017) . Thus, neurosuggestion, rather than the act of regulating one's own EEG waves, likely allows patients to break free from harmful looping effects.
In sum, under certain circumstances, clinicians could ethically and non-deceptively prescribe EEG-nf as a form of neurosuggestion therapy. It wouldn't be the first placebo prescription-in the United States, one study reports that 45% of physicians use placebos in clinical practice and 96% of them believe placebos can have therapeutic effects (Sherman & Hickner, 2008) ; in Canada, an analysis of placebo use among physicians, and especially psychiatrists, echoes similar sentiments (Raz et al., 2011) . Moreover, a recent study describes interviews with 1,000 parents and reports that most deem it acceptable for clinicians to recommend placebo treatment for ADHD (Faria et al., 2017) . With these realities in mind, EEGnf presents a reasonable alternative for patients experiencing adverse side-effects or simply searching for a non-pharmacological treatment. Because EEG-nf requires time, money, and energy, if clinicians decide to promote this technique, they ought to present it as one of several options (e.g., exercise, cognitive training, behavioral therapy, and diet; Sonuga- Barke et al., 2013) . Thus, clinicians can certainly prescribe EEG-nf. We recommend they do so transparently and with an eye for amplifying the psychosocial mechanisms of suggestion rather than grasping at the elusive neural signatures many practitioners speciously assign as the cause of ADHD.
